Send to printer »

GEN News Highlights : Apr 25, 2011

Nano Terra and Kadmon Establish JV to Develop Three Drugs and Pharmacomer Platform

Kadmon gets worldwide license to IP recently acquired by Nano Terra from Surface Logix.

Kadmon Pharmaceuticals and Nano Terra are establishing a joint venture (JV), NT Life Sciences, to develop three of Nano Terra’s clinical-stage drug candidates, SLx-2119, SLx-4009, and SLx-2101, and its Pharmacomer™ drug discovery platform. Under terms of the deal Kadmon has negotiated a worldwide, exclusive license to the three drugs along with rights to the discovery platform.

SLx-2119, SLx-4090, and SLx-2101 and the Pharmacomer platform were originally developed by Surface Logix, which Nano Terra recently acquired. The three compounds are in early- to mid-stage development for a range of diseases.

SLx-2119 targets the Rho-associated coiled-coiled kinase 2 (ROCK2) pathway. SLx-4090 targets the MTP (enterocytic microsomal triglyceride transfer protein) pathway, and SLx-2101 targets PDE5 (phosphodiesterase 5).

Nano Terra and Kadmon claim preclinical studies suggest SLX-2119 may have therapeutic applications in a broad spectrum of diseases including metabolic syndrome, diabetes, cancer, autoimmune diseases, and spinal cord injury. As for SLx-2101, Surface Logix previously completed four Phase IIa studies in hypertension, Raynaud's disease, and erectile dysfunction.

SLx-4090 has been designed to treat metabolic and cardiovascular diseases without the associated toxicity issues inherent in systemic MTP inhibition, the firm adds. Orally administered SLx-4090 targets MTP only in enterocytes of the small intestine, blocking a key step in the adsorption of dietary triglycerides and cholesterol into the lymphatic circulation, Surface Logix claims. Moreover, the firm adds, because SLx-4090 does not enter the systemic circulation it avoids mechanistic toxicities that are associated with systemic MTP inhibition, such as fatty liver.